Biopharmaceutical companies increase R&D investment
The production capacity of florfenicol raw materials is limited or there may be an oversold rebound.
After the Spring Festival, as the veterinary raw material drug market rose to a high level, the market began to weaken, and the veterinary raw material drug market showed a downward trend. However, with the arrival of the peak season for traditional demand, the veterinary raw material drug market may rebound.
Among the Veterinary Raw Materials monitored by the China Veterinary Drug and Feed Trading Center, the market prices of many varieties have dropped significantly.

However, with the advent of summer, the market trend of veterinary drug raw materials may usher in a wave of rebound, and the prices of some products may enter an upward channel.
First, the veterinary raw material drug market is about to enter the peak season of traditional demand, and the downstream market demand is gradually increasing. The rigid demand restricts the downside of the raw material drug market.
Second, the cumulative increase in external factors, environmental protection, security inspections and other factors may cause some companies to restrict or even stop production, and the supply of veterinary raw materials in the veterinary drug market has tightened. The upstream raw material plant of FLORFENICOL has been suspended due to environmental protection. Recently, the news has been released. The florfenicol plant has a high price mentality, and the market has responded positively and focused attention.
Third, the summer high temperature maintenance season is coming. Historical data shows that the high temperature maintenance of mainstream manufacturers will have a greater impact on product market prices.
Fourth, the early-stage demand has weakened, shipments are not smooth, intermediate channels have reduced prices for shipments, withdrawn funds, some channels have been oversold, and inventories have dropped to low levels. Once market demand improves, full replenishment of the industry chain will be triggered, which may be promoted by then Product prices are rising rapidly.
2026-10-14
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Can China's Biomedical Industry Revolutionize Healthcare with Innovation and Growth?
-
The 2022 edition of the list of the world's top 2 percent scientists has been announced: Dr. Liu Yongjun, president of Cinda Bio, is on it!
-
Three Chains Fusion' of Zhuhai Biomedical Industry
-
135 biomedical companies forecast nearly 60% year-on-year growth
-
An Explosion Has Occurred in the Jubail Industrial City, Putting 6–8% of Global Petrochemical Production Capacity at Risk
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
When Light Falls on Metal: The Industrial Romance of Xiaomi × BASF
-
LBB Specialties to Distribute Imerys' Mineral Ingredients in North America
-
AkzoNobel Invests €50 Million to Expand Aerospace Coatings Operations in the United States
-
Sinopec and LG Chem Sign Agreement to Jointly Develop Sodium-Ion Battery Materials
Recommend Reading
-
BASF’s Zhanjiang Integrated Site Commissions New Neopentyl Glycol (NPG) Unit
-
Ineos Rescues UK's Last Dichloroethane Plant
-
BASF and IFF Collaborate to Accelerate Innovation in Enzymes and Polymers
-
BASF Raises Acid Chloride and Chloroformate Capacity by 30% at Ludwigshafen
-
BASF Sues Apple Over Face Authentication Patents Used in Dozens of iPhones and iPads
-
Business Society September 28, 2026 Urea Trend Analysis: Volatile with a Slight Bullish Bias
-
Business Society September 28, 2026 Phthalic Anhydride Trend Analysis: Weakly Bearish
-
Business Society’s MTBE Market Outlook on September 3, 2026: Volatile Consolidation
-
Business Society September 28, 2026 Propylene Oxide Trend Analysis: Volatility
-
Business Society’s MTBE Market Outlook on September 2, 2026: Weak Rebound